Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A pharmaceutical composition comprising a probiotic and a prebiotic to prevent acquisition of or treat drug resistant infections

A technology of composition and probiotics, applied in the direction of drug combination, anti-infective drug, pharmaceutical formula, etc.

Pending Publication Date: 2020-08-04
CHR HANSEN AS
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, prebiotics alone have not been shown to have this effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical composition comprising a probiotic and a prebiotic to prevent acquisition of or treat drug resistant infections
  • A pharmaceutical composition comprising a probiotic and a prebiotic to prevent acquisition of or treat drug resistant infections
  • A pharmaceutical composition comprising a probiotic and a prebiotic to prevent acquisition of or treat drug resistant infections

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0057] According to a preferred embodiment of the present invention, the prebiotics include one or more of the following: (a) oligosaccharides, (b) fructooligosaccharides ("FOS"), such as soybean fructooligosaccharides, inulin or banana Fiber, (c) pectin or pectin polysaccharide, (d) mannan, such as guar gum, locust bean gum, konjac or xanthan gum, (e) pentosan, beta-glucan, arabican Sugars and galactans, such as larch arabinogalactan, and (f) mixtures thereof.

[0058] According to one embodiment, the pharmaceutical composition of the present disclosure may be administered in a solid, semi-solid or liquid oral dosage form. In one embodiment of the present disclosure, the pharmaceutical formulations may be in the form of emulsions, solutions, suspensions, syrups, elixirs, tablets, capsules, pills, granules and suppositories. In another embodiment of the present disclosure, the pharmaceutical formulation can be water dispersible granules (WG), suspension concentrates (SC), wet...

Embodiment

[0095] Composition comprising Lactobacillus plantarum ATCC 202195 and fructooligosaccharides

[0096] Powder formulations as shown in Table 1 below were prepared, each formulation including Lactobacillus plantarum ATCC 202195, fructooligosaccharide and maltodextrin.

[0097] Table 1: Powder Formulations

[0098]

[0099] Each of the above formulations 1 to 3 was packaged in a sachet and stored in a cool, moisture-proof container for further use.

[0100]Administration of Lactobacillus plantarum ATCC 202195 and fructooligosaccharides to infants

[0101] A cohort of infants was born orally administered a synergistic biologic containing Lactobacillus plantarum ATCC 202195 and fructooligosaccharides. Newborns were recruited from over 70 community sites and two tertiary care centers in Odisha, India - Capital Hospital, Bhubaneswar and SCB Medical College, Cuttack. All infants were more than 35 weeks' gestation and weighed more than 1800 grams at birth. The group designated a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a pharmaceutical composition comprising a probiotic and a prebiotic for preventing acquisition of and / or alleviating symptoms associated with an infection caused by an Extended-spectrum beta-lactamases (ESBL) producing organism and other drug resistant pathogens. More particularly, the pharmaceutical composition comprises at least one Lactillobacillus specie(s) as aprobiotic and at least one oligosaccharide as a prebiotic. The present invention further provides a method of preventing acquisition of and / or treating an infection caused by Extended-spectrum beta-lactamases (ESBL) producing bacteria and other drug resistant pathogens, comprising administering an effective amount of a pharmaceutical composition comprising a probiotic and a prebiotic to a subjectin need thereof.

Description

technical field [0001] The present invention relates to a pharmaceutical composition comprising probiotics and prebiotics for the prevention and / or remission of mammals from infection and / or relief from bacteria containing extended-spectrum beta-lactamases (ESBL) and other drug-resistant pathogens Symptoms associated with the infection. More specifically, the present invention relates to a composition comprising at least one Lactobacillus species as a probiotic and at least one oligosaccharide as a prebiotic for preventing mammals from acquiring Lactamase-lactamase (ESBL) bacteria and other drug-resistant pathogens can cause infection and / or relieve symptoms associated with such infection. Background technique [0002] The Background Description includes information that may be helpful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, nor is it an admission...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/747
CPCA61K35/747A61K45/06A61K31/702A61K31/718A23L33/125A23L33/135A61P31/04A61K2300/00A61K31/732A61P31/00A61P37/00A61P1/00
Inventor 普拉瓦斯·兰詹·米斯拉
Owner CHR HANSEN AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com